Physician profile
Peter Tran
NPI 1508228859
$5,030.18
in general payments reported to CMS, 2019-2025
18 companies · $939 in 2025
The $939 reported for 2025 was more than what 78% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $335 · 2022: $1,181 · 2023: $1,474 · 2024: $1,102 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,384 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,383.62 |
| Education | $130.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $992.29 | 2021-2025 | Cabenuva, Dovato, Apretude |
| Gilead Sciences, INC. | $969.31 | 2021-2025 | Biktarvy |
| Paratek Pharmaceuticals, INC. | $756.43 | 2022-2025 | Nuzyra |
| Abbvie INC. | $672.83 | 2021-2025 | Dalvance, Mavyret, Avycaz |
| Insmed, INC. | $438.28 | 2021-2025 | Arikayce |
| Melinta Therapeutics, LLC | $348.00 | 2023-2025 | Kimyrsa, Rezzayo, Vabomere |
| Astellas Pharma US INC | $296.92 | 2022-2024 | Cresemba |
| Merck Sharp & Dohme LLC | $113.39 | 2023-2025 | Dificid, Zerbaxa, Recarbrio |
| Aimmune Therapeutics, INC. | $93.99 | 2024-2025 | Vowst |
| Glaxosmithkline, LLC. | $71.97 | 2023-2025 | Arexvy, Shingrix |
| Shionogi INC | $57.16 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $47.73 | 2022 | |
| Theratechnologies INC. | $36.77 | 2023 | Egrifta, Trogarzo |
| Vbi Vaccine (Delaware) INC. | $36.28 | 2022-2023 | Prehevbrio |
| Cumberland Pharmaceuticals, INC. | $32.45 | 2025 | Vibativ |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $26.72 | 2025 | Heplisav-B |
| La Jolla Pharmaceutical Company | $23.66 | 2022 | |
| Pfizer INC. | $16.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.